Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict | Los Angeles Business Journal
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ… https://t.co/sWLJCNJzQV"
HCW starts Puma Biotechnology at buy; PT $15 | BioTuesdays
$51.61 Million in Sales Expected for Puma Biotechnology, Inc. (NASDAQ:PBYI) This Quarter - Opera News
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters
Puma Shares Soar 81% Over 2 Days | Los Angeles Business Journal
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology (NASDAQ:PBYI) Announces Earnings Results, Beats Estimates By $0.11 EPS - Opera News
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Here's Why Puma Biotechnology Inc (NASDAQ:PBYI) Is Running Up - Market Exclusive